China · Delayed Price · Currency is CNY Sirio Pharma Statistics
Total Valuation
Sirio Pharma has a market cap or net worth of CNY 6.98 billion. The enterprise value is 8.23 billion.
| Market Cap | 6.98B |
| Enterprise Value | 8.23B |
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | May 27, 2025 |
Share Statistics
Sirio Pharma has 305.65 million shares outstanding. The number of shares has increased by 0.12% in one year.
| Current Share Class | 305.65M |
| Shares Outstanding | 305.65M |
| Shares Change (YoY) | +0.12% |
| Shares Change (QoQ) | -0.15% |
| Owned by Insiders (%) | 20.76% |
| Owned by Institutions (%) | 17.65% |
| Float | 110.79M |
Valuation Ratios
The trailing PE ratio is 20.15 and the forward PE ratio is 19.07.
| PE Ratio | 20.15 |
| Forward PE | 19.07 |
| PS Ratio | 1.57 |
| PB Ratio | 2.54 |
| P/TBV Ratio | 4.11 |
| P/FCF Ratio | 33.83 |
| P/OCF Ratio | 10.03 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.68, with an EV/FCF ratio of 39.89.
| EV / Earnings | 23.81 |
| EV / Sales | 1.85 |
| EV / EBITDA | 12.68 |
| EV / EBIT | 17.90 |
| EV / FCF | 39.89 |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.89 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 2.61 |
| Debt / FCF | 8.27 |
| Interest Coverage | 21.38 |
Financial Efficiency
Return on equity (ROE) is 10.94% and return on invested capital (ROIC) is 6.77%.
| Return on Equity (ROE) | 10.94% |
| Return on Assets (ROA) | 5.18% |
| Return on Invested Capital (ROIC) | 6.77% |
| Return on Capital Employed (ROCE) | 9.66% |
| Revenue Per Employee | 1.60M |
| Profits Per Employee | 124,470 |
| Employee Count | 2,776 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 5.57 |
Taxes
In the past 12 months, Sirio Pharma has paid 38.53 million in taxes.
| Income Tax | 38.53M |
| Effective Tax Rate | 11.69% |
Stock Price Statistics
The stock price has increased by +11.58% in the last 52 weeks. The beta is 0.32, so Sirio Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +11.58% |
| 50-Day Moving Average | 24.17 |
| 200-Day Moving Average | 22.20 |
| Relative Strength Index (RSI) | 53.42 |
| Average Volume (20 Days) | 2,161,865 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sirio Pharma had revenue of CNY 4.45 billion and earned 345.53 million in profits. Earnings per share was 1.13.
| Revenue | 4.45B |
| Gross Profit | 1.42B |
| Operating Income | 462.78M |
| Pretax Income | 329.66M |
| Net Income | 345.53M |
| EBITDA | 617.17M |
| EBIT | 462.78M |
| Earnings Per Share (EPS) | 1.13 |
Balance Sheet
The company has 551.95 million in cash and 1.71 billion in debt, giving a net cash position of -1.15 billion or -3.78 per share.
| Cash & Cash Equivalents | 551.95M |
| Total Debt | 1.71B |
| Net Cash | -1.15B |
| Net Cash Per Share | -3.78 |
| Equity (Book Value) | 2.75B |
| Book Value Per Share | 8.69 |
| Working Capital | 972.44M |
Cash Flow
In the last 12 months, operating cash flow was 695.53 million and capital expenditures -489.27 million, giving a free cash flow of 206.27 million.
| Operating Cash Flow | 695.53M |
| Capital Expenditures | -489.27M |
| Free Cash Flow | 206.27M |
| FCF Per Share | 0.67 |
Margins
Gross margin is 31.98%, with operating and profit margins of 10.39% and 7.76%.
| Gross Margin | 31.98% |
| Operating Margin | 10.39% |
| Pretax Margin | 7.40% |
| Profit Margin | 7.76% |
| EBITDA Margin | 13.86% |
| EBIT Margin | 10.39% |
| FCF Margin | 4.63% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 2.16%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 2.16% |
| Dividend Growth (YoY) | -23.18% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 49.89% |
| Buyback Yield | -0.12% |
| Shareholder Yield | 2.04% |
| Earnings Yield | 4.95% |
| FCF Yield | 2.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 27, 2025. It was a forward split with a ratio of 1.3.
| Last Split Date | May 27, 2025 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |